Effects of dosage, comorbidities, and food on Isoniazid pharmacokinetics in peruvian tuberculosis patients

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 12, 2014, Pages 7164-7170

  Requena Méndez, Ana ^a,b   Davies, Geraint ^c   Waterhouse, David ^d   Ardrey, Alison ^d   Jave, Oswaldo ^e   López Romero, Sonia Llanet ^a   Ward, Stephen A ^d   Moore, David A J ^a,f  

^a UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^b CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^e HOSPITAL NACIONAL DOS DE MAYO   (Peru)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIDIABETIC AGENT; FAT INTAKE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; COMORBIDITY; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DRUG HALF LIFE; FEMALE; FOOD DRUG INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; OUTCOME ASSESSMENT; PERUVIAN; RECOMMENDED DRUG DOSE; TREATMENT RESPONSE; TUBERCULOSIS; ADOLESCENT; DRUG ADMINISTRATION; FAT INTAKE; HIV INFECTIONS; METABOLISM; MIDDLE AGED; PATHOLOGY; PERU; PHARMACOKINETICS; SEX DIFFERENCE; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; COMORBIDITY; DIABETES MELLITUS; DIETARY FATS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOOD-DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; HYPOGLYCEMIC AGENTS; ISONIAZID; MALE; MIDDLE AGED; PERU; RIFAMPIN; SEX FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84912096005     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03258-14     Document Type: Article

References (36)

1. Harries AD, Zachariah R, Corbett EL, Lawn SD, Santos-Filho ET, Chimzizi R, Harrington M, Maher D, Williams BG, De Cock KM. 2010. The HIV-associated tuberculosis epidemic-when will we act? Lancet 375:1906-1919. http://dx.doi.org/10.1016/S0140-6736(10)60409-6.
2. Ahmad Khan F, Minion J, Al-Motairi A, Benedetti A, Harries AD, Menzies D. 2012. An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection. Clin. Infect. Dis. 55:1154-1163. http://dx.doi.org/10.1093/cid/cis630.
3. Baker MA, Harries AD, Jeon CY, Hart JE, Kapur A, Lonnroth K, Ottmani SE, Goonesekera SD, Murray MB. 2011. The impact of diabetes on tuberculosis treatment outcomes: a systematic review.BMCMed. 9:81. http://dx.doi.org/10.1186/1741-7015-9-81.
4. Harries AD, Lin Y, Satyanarayana S, Lonnroth K, Li L, Wilson N, Chauhan LS, Zachariah R, Baker MA, Jeon CY, Murray MB, Maher D, Bygbjerg IC, Enarson DA, Billo NE, Kapur A. 2011. The looming epidemic of diabetes-associated tuberculosis: learning lessons from HIVassociated tuberculosis. Int. J. Tuberc. Lung Dis. 15:1436-1444, i. http: //dx.doi.org/10.5588/ijtld.11.0503.
5. WHO. 2010. Guidelines for treatment of tuberculosis. WHO, Geneva, Switzerland.
6. Menzies D, Benedetti A, Paydar A, Martin I, Royce S, Pai M, Vernon A, Lienhardt C, Burman W. 2009. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med. 6:e1000146. http://dx.doi.org/10.1371/journal .pmed.1000146.
7. Jasmer RM, Seaman CB, Gonzalez LC, Kawamura LM, Osmond DH, Daley CL. 2004. Tuberculosis treatment outcomes: directly observed therapy compared with self-administered therapy. Am. J. Respir. Crit. Care Med. 170:561-566. http://dx.doi.org/10.1164/rccm.200401-095OC.
8. Hesseling AC, Walzl G, Enarson DA, Carroll NM, Duncan K, Lukey PT, Lombard C, Donald PR, Lawrence KA, Gie RP, van Helden PD, Beyers N. 2010. Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. Int. J. Tuberc. Lung Dis. 14:560-570.
9. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. 2001. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 358:1687-1693. http://dx.doi.org/10.1016/S0140-6736(01)06712-5.
10. Korenromp EL, Scano F, Williams BG, Dye C, Nunn P. 2003. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin. Infect. Dis. 37: 101-112. http://dx.doi.org/10.1086/375220.
11. Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, Reingold AL, Kenyon TA, Moeti TL, Tappero JW. 2009. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin. Infect. Dis. 48:1685-1694. http://dx.doi.org/10.1086/599040.
12. Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE. 1998. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 113:1178-1183. http://dx.doi.org/10.1378 /chest.113.5.1178.
13. Mehta JB, Shantaveerapa H, Byrd RP, Jr, Morton SE, Fountain F, Roy TM. 2001. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest 120:1520-1524. http://dx.doi .org/10.1378/chest.120.5.1520.
14. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. 2006. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob. Agents Chemother. 50: 1170 -1177. http://dx.doi.org/10.1128/AAC.50 .4.1170-1177.2006.
15. Burhan E, Ruesen C, Ruslami R, Ginanjar A, Mangunnegoro H, Ascobat P, Donders R, van Crevel R, Aarnoutse R. 2013. Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. Antimicrob. Agents Chemother. 57: 3614-3619. http://dx.doi.org/10.1128 /AAC.02468-12.
16. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharat S, Shandil RK, Kantharaj E, Balasubramanian V. 2003. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 47:2118-2124. http://dx.doi.org/10.1128/AAC.47.7.2118-2124.2003.
17. Jayaram R, Shandil RK, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Kantharaj E, Balasubramanian V. 2004. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 48:2951-2957. http://dx.doi.org/10.1128/AAC.48.8.2951-2957.2004.
18. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. 2013. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J. Infect. Dis. 208:1464-1473. http://dx.doi.org/10.1093/infdis /jit352.
19. Pasipanodya J, Gumbo T. 2011. An oracle: antituberculosis pharmaco-kinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrob. Agents Chemother. 55:24-34. http://dx.doi.org/10.1128/AAC.00749-10.
20. Peloquin CA. 2002. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 62:2169-2183. http://dx.doi.org/10.2165/00003495 -200262150-00001.
21. Nijland HM, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RH, van der Ven AJ, Danusantoso H, Aarnoutse RE, van Crevel R. 2006. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin. Infect. Dis. 43:848-854. http://dx.doi .org/10.1086/507543.
22. Ruslami R, Nijland HM, Adhiarta IG, Kariadi SH, Alisjahbana B, Aarnoutse RE, van Crevel R. 2010. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob. Agents Chemother. 54:1068-1074. http://dx.doi.org/10.1128/AAC .00447-09.
23. Mitchison DA. 1979. Basic mechanisms of chemotherapy. Chest 76 (6 Suppl):771-781. http://dx.doi.org/10.1378/chest.76.6-Supplement.771.
24. Parkin DP, Vandenplas S, Botha FJ, Vandenplas ML, Seifart HI, van Helden PD, van der Walt BJ, Donald PR, van Jaarsveld PP. 1997. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am. J. Respir. Crit. Care Med. 155:1717-1722. http://dx .doi.org/10.1164/ajrccm.155.5.9154882.
25. Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, Jones B, Silva-Trigo C, Zhao Z, Hodge T. 2005. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin. Infect. Dis. 40:1481-1491. http://dx.doi.org/10.1086/429321.
26. Weiner M, Burman W, Vernon A, Benator D, Peloquin CA, Khan A, Weis S, King B, Shah N, Hodge T. 2003. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am. J. Respir. Crit. Care Med. 167:1341-1347. http://dx.doi .org/10.1164/rccm.200208-951OC.
27. Requena-Méndez A, Davies G, Ardrey A, Jave O, Lopez-Romero SL, Ward SA, Moore DA. 2012. Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV. Antimicrob. Agents Chemother. 56:2357-2363. http://dx.doi.org/10.1128 /AAC.06059-11.
28. Sabbagh A, Langaney A, Darlu P, Gerard N, Krishnamoorthy R, Poloni ES. 2008. Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genet. 9:21. http://dx.doi.org/10.1186 /1471-2156-9-21.
29. Mitchell RS, Bell JC. 1957. Clinical implications of isoniazid blood levels in pulmonary tuberculosis. N. Engl. J. Med. 257:1066-1070. http://dx.doi .org/10.1056/NEJM195711282572202.
30. Selkon JB, Fox W, Gangadharam PR, Ramachandran K, Ramakrishnan CV, Velu S. 1961. Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis. 2. Clinical implications in the treatment of pulmonary tuberculosis with isoniazid either alone or in combination with PAS. Bull. World Health Organ. 25:779-792.
31. Gangadharam PR, Devadatta S, Fox W, Nair CN, Selkon JB. 1961. Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis. Serum concentrations of isoniazid produced by three regimens of isoniazid alone and one of isoniazid plus PAS. Bull. World Health Organ. 25:793-806.
32. Donald PR, Sirgel FA, Venter A, Parkin DP, Seifart HI, van de Wal BW, Werely C, van Helden PD, Maritz JS. 2004. The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid. Clin. Infect. Dis. 39:1425-1430. http://dx.doi.org/10.1086/424999.
33. Bhusal Y, Shiohira CM, Yamane N. 2005. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 26:292-297. http://dx.doi .org/10.1016/j.ijantimicag.2005.05.005.
34. Rey-Jurado E, Tudo G, Martinez JA, Gonzalez-Martin J. 2012. Synergistic effect of two combinations of antituberculous drugs against Mycobacterium tuberculosis. Tuberculosis (Edinb.) 92:260-263. http://dx.doi .org/10.1016/j.tube.2012.01.005.
35. Chang KC, Leung CC, Grosset J, Yew WW. 2011. Treatment of tuberculosis and optimal dosing schedules. Thorax 66:997-1007. http://dx.doi .org/10.1136/thx.2010.148585.
36. Cox HS, Morrow M, Deutschmann PW. 2008. Long term efficacy of DOTS regimens for tuberculosis: systematic review. BMJ 336:484-487. http://dx.doi.org/10.1136/bmj.39463.640787.BE.